IMAGE A1M.SE

GUARD THERAPEUTICS

MARKET CAP - 154M SEK
MARKET CAP - 154M SEK

ABOUT US

The fight against acute kidney injury Guard Therapeutics was founded in 2008 by researchers at the University of Lund, Sweden. The goal is to develop and commercialize the product candidate ROSgard, and thereby contribute to a better and less harmful treatment of acute kidney disease. The drug candidate ROSgard’s key characteristics prevent damage from oxidative stress by protecting, cleaning and repairing exposed tissue. The kidneys are organs that are especially sensitive to damage related to oxidative stress. Guard Therapeutics has chosen to focus its clinical development on acute kidney damage associated with heart surgery. This is considered to be a very attractive indication based on ROSgard’s mode of action, available preclinical data and developmental advantages. Treatment with ROSgard could save lives and prevent such chronic and grave consequences from reduced kidney function as life-supporting dialysis.

Q&A WITH TOBIAS AGERVALD  

Right arrow

What have been the milestones so far in your company development?

Awaiting.

Right arrow

What are your most important markets, segments and customers?

Awaiting.

Right arrow

Where do you see the company five years from now?

Awaiting.

Right arrow

What are your priorities within 2020/21?

Awaiting.

Right arrow

Why should one consider adding your company into their portfolio?

Awaiting.

PRODUCTS & SERVICES

MEDIA